menu
    • menu
    [{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"APG777","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.47999999999999998,"dosageForm":"Injectable\/Injection","sponsorNew":"Apogee Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Apogee Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"APG777","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Apogee Therapeutics","amount2":0.26000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.47999999999999998,"dosageForm":"Injectable\/Injection","sponsorNew":"Apogee Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Apogee Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"APG777","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Apogee Therapeutics","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.47999999999999998,"dosageForm":"Injectable\/Injection","sponsorNew":"Apogee Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Apogee Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"APG777","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Apogee Therapeutics","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.47999999999999998,"dosageForm":"Injectable\/Injection","sponsorNew":"Apogee Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Apogee Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"APG777","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Apogee Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apogee Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"APG777","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Apogee Therapeutics","amount2":0.41999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.47999999999999998,"dosageForm":"Injection","sponsorNew":"Apogee Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Apogee Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"APG808","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apogee Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Apogee Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"APG777","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Apogee Therapeutics","amount2":0.47999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.47999999999999998,"dosageForm":"Injection","sponsorNew":"Apogee Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Apogee Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"APG990","moa":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Apogee Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Apogee Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"APG333","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Apogee Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Apogee Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"APG777","moa":"IL-13","graph1":"Dermatology","graph2":"Phase II","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apogee Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apogee Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Apogee Therapeutics

    Menu

    Apogee Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Apogee Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Apogee Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : APG777

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Apogee Doses First Patient in Part B of Phase 2 APEX Trial for APG777 in Atopic Dermatitis

                            Details : APG777 is a IL-13 inhibitor antibody candidate, which is being evaluated in clinical trial studies for the treatment of patients with atopic dermatitis.

                            Product Name : APG777

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            February 03, 2025

                            Lead Product(s) : APG777

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Apogee Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Apogee Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : APG333

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Apogee Doses First Participants in Phase 1 APG333 Trial for Respiratory Conditions

                            Details : APG333 is a novel, SQ extended half-life mAb targeting TSLP, a key driver of Type 2 and Type 3 inflammation in eosinophilic and non-eosinophilic conditions, like asthma, COPD.

                            Product Name : Undisclosed

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 10, 2024

                            Lead Product(s) : APG333

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Apogee Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Apogee Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : APG990

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Apogee Therapeutics Begins Phase 1 Trial of APG990 for Inflammatory Diseases

                            Details : APG990 is a novel, SQ half-life extended monoclonal antibody which works by targeting OX40L, it is currently being developed for Atopic dermatitis.

                            Product Name : APG990

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 19, 2024

                            Lead Product(s) : APG990

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Apogee Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Apogee Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : APG808

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Apogee Doses First Patients in APG808 Phase 1 for COPD and Inflammatory Diseases

                            Details : APG808 is a novel subcutaneous extended half-life monoclonal antibody (mAb) targeting IL-4Rα, which is being developed for people living with moderate-to-severe COPD, asthma and other I&I diseases.

                            Product Name : APG808

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 25, 2024

                            Lead Product(s) : APG808

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Apogee Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Apogee Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : APG777

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Jefferies

                            Deal Size : $483.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Apogee Closes Upsized Offering, Raising $483 Million

                            Details : The company will use proceeds to fund clinical trials and manufacturing of APG777, a subcutaneous monoclonal antibody targeting IL-13 for moderate-to-severe atopic dermatitis and asthma.

                            Product Name : APG777

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 12, 2024

                            Lead Product(s) : APG777

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Jefferies

                            Deal Size : $483.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Apogee Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Apogee Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : APG777

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Jefferies

                            Deal Size : $420.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Apogee Announces $420M Public Offering for Therapeutics Expansion

                            Details : The net proceeds will be used in the clinical advancement of Apogee lead product APG777, which is being evaluated in Phase I clinical trial studies for Atopic dermatitis and also including Asthma.

                            Product Name : APG777

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 07, 2024

                            Lead Product(s) : APG777

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Jefferies

                            Deal Size : $420.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Apogee Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Apogee Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : APG777

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Ex...

                            Details : APG777 is a novel, subcutaneous extended half-life monoclonal antibody targeting IL-13 – a critical cytokine in inflammation and a primary driver of Atopic Dermatitis and Other Inflammatory Diseases.

                            Product Name : APG777

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 07, 2023

                            Lead Product(s) : APG777

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Apogee Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Apogee Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : APG777

                            Therapeutic Area : Dermatology

                            Study Phase : Preclinical

                            Sponsor : Jefferies

                            Deal Size : $345.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Apogee Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underw...

                            Details : The net proceeds will fund company's clinical trials, including a potential Phase 2 trial, and manufacturing of its APG777, APG808, APG990 and APG222 programs, fund its preclinical studies, clinical trials.

                            Product Name : APG777

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 18, 2023

                            Lead Product(s) : APG777

                            Therapeutic Area : Dermatology

                            Highest Development Status : Preclinical

                            Sponsor : Jefferies

                            Deal Size : $345.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Apogee Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Apogee Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : APG777

                            Therapeutic Area : Dermatology

                            Study Phase : Preclinical

                            Sponsor : Jefferies

                            Deal Size : $300.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Apogee Therapeutics, Inc. Announces Pricing of Upsized Initial Public Offering

                            Details : The net proceeds will fund company's clinical trials, including a potential Phase 2 trial, and manufacturing of its APG777, APG808, APG990 and APG222 programs, fund its preclinical studies, clinical trials.

                            Product Name : APG777

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 13, 2023

                            Lead Product(s) : APG777

                            Therapeutic Area : Dermatology

                            Highest Development Status : Preclinical

                            Sponsor : Jefferies

                            Deal Size : $300.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Apogee Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Apogee Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : APG777

                            Therapeutic Area : Dermatology

                            Study Phase : Preclinical

                            Sponsor : Jefferies

                            Deal Size : $263.1 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Apogee Therapeutics to Raise up to $263.1M in IPO

                            Details : The net proceeds will fund company's clinical trials, including a potential Phase 2 trial, and manufacturing of its APG777, APG808, APG990 and APG222 programs, fund its preclinical studies, clinical trials.

                            Product Name : APG777

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 10, 2023

                            Lead Product(s) : APG777

                            Therapeutic Area : Dermatology

                            Highest Development Status : Preclinical

                            Sponsor : Jefferies

                            Deal Size : $263.1 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth